This week's roundup of Houston innovators includes Zain Shauk of Dream Harvest, Juliana Garaizar of Greentown Houston, and Jay Manouchehri of Fluence Analytics. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from sustainability to chemical analytics — recently making headlines in Houston innovation.

Zain Shauk, CEO of Dream Harvest

Zain Shauk, co-founder and CEO of Dream Harvest, joins the Houston Innovators Podcast just ahead of Earth Day. Photo courtesy of Dream Harvest

Zain Shauk is focused on future of farming, and the industry's success depends on making more environmentally friendly changes to the supply chain, and new technologies are enabling vertical indoor farming to effect these changes in some part. Shauk's company Dream Harvest recently received a $50 million investment from Orion Energy Partners to open a 100,000-square-foot indoor farming facility in Houston to scale production.

Shauk says he's also using the funding to support research and development to expand into other types of produce, but he has a lot to consider — affordability of the produce, maintaining sustainability, and more.

"It's going to take a lot of work and a lot of research. What I do know is we've come a long way with leafy greens," Shauk says. "When we started, we weren't growing in a way that makes financial sense with the amount of money we have to spend growing the product — and now we do." Click here to read more.

Juliana Garaizar, head of the Houston incubator and vice president of innovation

Greentown Houston's first year was surprising for Juliana Garaizar. Photo courtesy

Greentown Houston opened a year ago and, in just those 365 days, grew to over 60 member companies – something that took the original Boston-area location years. Juliana Garaizar says in a recent Q&A that this is due to companies outside of Houston looking for an entry point into the city for access to businesses, employees, and more. Specifically, she calls out Austin companies and businesses from Latin America.

"There are plenty of companies from Latin America coming over and choosing Houston as a landing pad and choosing Greentown as the place to start settling," she says. "We help them with funding. We help them with hiring local people." Click here to read more.

Jay Manouchehri, CEO of Fluence Analytics

Jay Manouchehri is now CEO of Fluence Analytics, and co-founder Alex Reed has transitioned to president and chief commercial officer. Photo courtesy of Fluence Analytics

Fluence Analytics, which moved its headquarters to the Houston area from New Orleans last year, has named Jay Manouchehri as the company's CEO. Manouchehri has worked in leadership roles within digital transformation at ABB and Honeywell all around the world, as well as in consulting and private equity.

Manouchehri tells InnovationMap he is focused on leading industrial growth.

“The next step for Fluence is really that we are industrializing our product and getting it into the industrial market," Manouchehri says. "That's exactly why we moved to Houston — it's where a lot of our clients are. We're building up and structure the company in such a manner that it could scale, get the right partnerships, and hire a team to take us to the next level and deliver the technology." Click here to read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.

Texas universities develop innovative open-source platform for cell analysis

picture this

What do labs do when faced with large amounts of imaging data? Powerful cloud computing systems have long been the answer to that question, but a new riposte comes from SPACe.

That’s the name of a new open-source image analysis platform designed by researchers at Baylor College of Medicine, Texas A&M University and the University of Houston.

SPACe, or Swift Phenotypic Analysis of Cells, was created to be used on standard computers that even small labs can access, meaning cellular analysis using images produced through cell painting has a lower barrier to entry than ever before.

“The pharmaceutical industry has been accustomed to simplifying complex data into single metrics. This platform allows us to shift away from that approach and instead capture the full diversity of cellular responses, providing richer, more informative data that can reveal new avenues for drug development,” Michael Mancini, professor of molecular and cellular biology and director of the Gulf Coast Consortium Center for Advanced Microscopy and Image Informatics co-located at Baylor College of Medicine and TAMU Institute for Bioscience and Technology.

SPACe is not only accessible because of its less substantial computational needs. Because the platform is open-source, it’s available to anyone who needs it. And it can be used by academic and pharmaceutical researchers alike.

“The platform allows for the identification of non-toxic effects of drugs, such as alterations in cell shape or effects on specific organelles, which are often overlooked by traditional assays that focus largely on cell viability,” says Fabio Stossi, currently a senior scientist with St. Jude Children’s Research Hospital, the lead author who was at Baylor during the development of SPACe.

The platform is a better means than ever of analyzing thousands of individual cells through automated imaging platforms, thereby better capturing the variability of biological processes. Through that, SPACe allows scientists an enhanced understanding of the interactions between drugs and cells, and does it on standard computers, translating to scientists performing large-scale drug screenings with greater ease.

"This tool could be a game-changer in how we understand cellular biology and discover new drugs. By capturing the full complexity of cellular responses, we are opening new doors for drug discovery that go beyond toxicity,” says Stossi.

And the fact that it’s open-source allows scientists to access SPACe for free right now. Researchers interested in using the platform can access it through Github at github.com/dlabate/SPACe. This early version could already make waves in research, but the team also plans to continually improve their product with the help of collaborations with other institutions.